In 2025, more Chinese companies chose to list in Hong Kong than in New York, marking a significant shift in the IPO market. Hong Kong’s stock exchange saw 46 China-domiciled companies raise HK$118.2 billion, compared to only 16 listings in the US totaling US$740.9 million.
Hong Kong’s appeal lies in new shares surging by 19.4% on average in their trading debuts, outperforming US listings. Amidst escalating US-China tensions and regulatory uncertainties, mainland firms prefer Hong Kong. The capital market shows signs of recovery, attracting companies like Innogen Pharmaceutical Group, whose shares soared almost fourfold last week.
The US-China rivalry extends to IPO markets, with Chinese companies shying away from US listings due to regulatory pressures. Conservative lawmakers’ opposition to funding China and executive orders targeting Chinese military companies have led to a decline in US investor interest in Chinese stocks.
Over the past decade, Hong Kong has emerged as a new IPO hotspot for Chinese companies, overtaking New York as the preferred listing destination. The shift was influenced by escalating US-China tensions, leading to regulatory uncertainties and a preference for the Hong Kong market among mainland firms. Amid auditing oversight tensions, the US and China averted expelling Chinese companies from New York in late 2022. Hong Kong emerged as a neutral ground for audit reviews. This led to a surge in Chinese companies listing in Hong Kong, with Alibaba leading the way with a US$12.9 billion IPO in 2019.
Improved investor sentiment and a streamlined IPO approval process by the Hong Kong exchange have fueled a boom in Chinese IPOs. Companies like CATL have led the way with mega deals, propelling Hong Kong to the world’s busiest IPO market. IPOs surged 695% in the first half of the year.
HKEX’s CEO Bonnie Chan Yiting announced a strong pipeline of companies seeking IPOs in Hong Kong, including many jumbo deals. HKEX reported record profits, signaling a bright future for IPOs in the region. The exchange’s new listing rules have attracted a variety of companies, making Hong Kong the second-largest IPO destination for biotech firms.
Three clusters of companies are tapping into Hong Kong’s IPO market: Chinese A-share companies seeking offshore funds, US-listed Chinese firms looking for a listing sanctuary, and specialist technology companies focused on AI, biomedicine, robotics, and other innovative industries. The HKEX’s listing rules have created opportunities for companies in these sectors to thrive. Hong Kong’s IPO market faces challenges due to limited liquidity, slowing listing approvals, and the influx of mainland companies. Analysts credit recent reforms and market mechanisms for boosting demand, but structural differences remain with the US market. Lower allocation ratios have led to strong aftermarket performance for retail investors.
Chinese companies listing in Hong Kong are experiencing massive oversubscriptions, with 71% closing higher on debut. Mixue Group and Chagee Holdings saw diverging sentiments in NY and HK, with Mixue soaring 47% and Chagee rising 16%. Chinese companies may prefer Hong Kong over the US for listings due to fundraising opportunities.
The choice between Hong Kong and the US for Chinese companies is becoming clearer, with the former offering better fundraising prospects. Mixue Group and Chagee Holdings’ successful debuts highlight the appeal of the Hong Kong market for Chinese firms seeking capital. 1. The United Nations reports that over 200 million people worldwide are at risk of losing their homes due to rising sea levels and extreme weather events caused by climate change. This highlights the urgent need for global action to reduce carbon emissions and protect vulnerable communities.
2. In a landmark decision, the European Union has approved a plan to phase out coal power plants by 2038 in an effort to combat climate change. This move is expected to significantly reduce carbon emissions and transition to cleaner energy sources.
3. A recent study published in a leading medical journal suggests that eating a diet high in fruits and vegetables can lower the risk of developing heart disease by up to 20%. This highlights the importance of a healthy diet in preventing chronic illnesses.
4. The World Health Organization warns that the global COVID-19 pandemic is far from over, with the emergence of new variants and uneven vaccination rates posing ongoing challenges. This underscores the need for continued vigilance and adherence to public health measures to control the spread of the virus.
Read more at Yahoo Finance: Hong Kong tops the US as the go-to IPO venue for Chinese start-ups as funds return to Asia